There is a newer version
of
this Section
2017 Kansas Statutes
Chapter 65 PUBLIC HEALTH
Article 6b AMYGDALIN (LAETRILE)
65-6b02 Same; use in treatment by physician, limitations on interference with.
Universal Citation: KS Stat § 65-6b02 (2017)
65-6b02. Same; use in treatment by physician, limitations on interference with. No medical care facility or other health care facility shall interfere with the physician-patient relationship by restricting or prohibiting the use of amygdalin (laetrile) as an adjunct to recognized, customary or accepted modes of therapy or by itself in the treatment of any malignancy, disease, illness or physical condition when amygdalin (laetrile) is prescribed or administered by a physician, and the patient has signed the written informed request therefor substantially as set forth in K.S.A. 65-6b05.
History: L. 1978, ch. 239, § 2; July 1.
Disclaimer: These codes may not be the most recent version. Kansas may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
